2-羟基-3-硝基-5-(三氟甲基)吡啶 | 33252-64-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-羟基-3-硝基-5-(三氟甲基)吡啶
• 中文别名: 3-硝基-5-(三氟甲基)吡啶-2-醇；2-羟基-3-硝基-5-三氟甲基吡啶
• 英文名称: 3-nitro-5-trifluoromethylpyridin-2-ol
• 英文别名: 2-hydroxy-3-nitro-5-(trifluoromethyl)pyridine
• CAS: 33252-64-1
• 化学式: C₆H₃F₃N₂O₃
• mdl: MFCD00153193
• 分子量: 208.097
• InChiKey: JYXKHKBZLLIWEV-UHFFFAOYSA-N

物化性质

• 熔点：
  189 °C
• 沸点：
  276.2±40.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  室温环境下。

SDS

Name:	3-Nitro-5-(trifluoromethyl)pyridin-2-ol 97% Material Safety Data Sheet
Synonym:	2-Hydroxy-3-nitro-5-(trifluoromethyl)pyridin
CAS:	33252-64-1

Section 1 - Chemical Product MSDS Name:3-Nitro-5-(trifluoromethyl)pyridin-2-ol 97% Material Safety Data Sheet
Synonym:2-Hydroxy-3-nitro-5-(trifluoromethyl)pyridin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
33252-64-1	3-Nitro-5-(trifluoromethyl)pyridin-2-o	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 33252-64-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 183 - 186 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H3F3N2O3
Molecular Weight: 208

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 33252-64-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Nitro-5-(trifluoromethyl)pyridin-2-ol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 33252-64-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 33252-64-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 33252-64-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-羟基-3-硝基-5-(三氟甲基)吡啶 在 盐酸 、 氯化亚砜 、 硫酸 、 盐酸羟胺 、 对甲苯磺酸 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 tin(ll) chloride 、 sodium hydroxide 、 三氯氧磷 作用下， 以 N-甲基吡咯烷酮 、 乙醇 、 水 、 甲苯 为溶剂， 反应 77.42h， 生成 3-氨基-6-甲氧基-N-[(2S)-3,3,3-三氟-2-羟基-2-甲基丙基]-5-(三氟甲基)-2-吡啶甲酰胺
  参考文献：
  名称：

  发现 Icenticaftor (QBW251)，一种囊性纤维化跨膜电导调节增强剂，对囊性纤维化和慢性阻塞性肺病具有临床疗效

  摘要：

  囊性纤维化跨膜电导调节器 (CFTR) 离子通道中的突变被确定为破坏性肺病囊性纤维化 (CF) 的主要致病因素。最近，香烟烟雾暴露已被证明与气道上皮离子转运功能障碍有关，这表明 CFTR 在慢性阻塞性肺病 (COPD) 的发病机制中起作用。在这里，报告了高通量筛选命中6作为突变人类 F508del 和野生型 CFTR 通道的增强剂的鉴定和表征。化合物7 – 33的设计、合成和生物学评价描述了建立支架的构效关系，从而确定了临床开发化合物 icenticaftor (QBW251) 33，该化合物随后取得了进展，为 CF 和 COPD 患者提供了两个积极的临床概念证明，现在正在进一步开发作为 COPD 患者的一种新型治疗方法。

  DOI：

  10.1021/acs.jmedchem.1c00343
• 作为产物：
  描述：

  2-氨基-5-三氟甲基吡啶 在 硫酸 、 硝酸 、 sodium nitrite 作用下， 以 水 为溶剂， 生成 2-羟基-3-硝基-5-(三氟甲基)吡啶
  参考文献：
  名称：

  New tetracyclic 1,4-oxazepines constructed via practically simple tandem condensation strategy from readily available synthons

  摘要：

  A streamlined synthetic methodology towards novel tetracyclic 1,4-oxazepines from readily available precursors is described. The compounds, designed as more soluble version of the earlier described, poorly soluble dibenzo[bf][1,4]oxazepines, were obtained in high yields and as a single regioisomer as a result of three tandem chemical events-nucleophilic aromatic substitution, Smiles rearrangement and denitrocyclization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.12.026
• 作为试剂：
  描述：

  3-甲基-2-丁醇 、 4,6-二氯水杨醛 在 2-羟基-3-硝基-5-(三氟甲基)吡啶 、 18-冠醚-6 、 potassium tert-butylate 、 palladium diacetate 、 silver trifluoroacetate 作用下， 反应 17.0h， 生成 methyl (E)-4-(2-(((2,4-dichloro-6-hydroxybenzylidene)amino)oxy)-3-methylbutyl) benzoate 、 dimethyl 4,4'-(2-(((2,4-dichloro-6-hydroxybenzylidene)amino)oxy)-3-methylbutane-1,1-diyl)(E)-dibenzoate
  参考文献：
  名称：

  被掩盖的脂肪醇的配体支持性β-亚甲基C（sp3）-H芳基化

  摘要：

  尽管有最新进展，但是反应性和位点选择性仍然是C（sp3）-H键官能化方法实际应用的重大障碍。在这里，我们描述了一个系统，该系统将水杨醛衍生的L，X型导向基团与缺电子的2-吡啶酮配体结合在一起，以使脂肪族醇的β-亚甲基C（sp3）-H芳基化以前有可能。值得注意的是，该方案与嵌入在醇底物和芳基偶联伙伴中的杂环兼容。二氢胆固醇的位点和立体特异性环合以及恩格列酮的关键中间体的合成说明了该方法的实用性。

  DOI：

  10.1002/anie.202000632

文献信息

• 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
  申请人：Xue Chu-Biao

  公开号：US20060004018A1

  公开（公告）日：2006-01-05

  The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及以下式的化合物： 这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
• 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors
  申请人：Xue Chu-Biao

  公开号：US20070149532A1

  公开（公告）日：2007-06-28

  The present invention is directed to compounds of Formula I: I which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及化合物I的化合物：I，这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
• HETEROCYCLIC DERIVATIVES
  申请人：Ahn Sung Oh

  公开号：US20110028467A1

  公开（公告）日：2011-02-03

  The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.

  本发明涉及杂环衍生物，更具体地，涉及用于制备治疗与尿酸相关疾病的药物的新颖杂环衍生物。
• [EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS<br/>[FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES EN TANT QU'INHIBITEURS DE JAK2
  申请人：AJAX THERAPEUTICS INC

  公开号：WO2021226261A1

  公开（公告）日：2021-11-11

  The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

  本公开提供了6-杂芳氧基苯并咪唑和氮杂苯并咪唑化合物及其组合物，用于抑制JAK2。
• [EN] N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-ARYLE MONOCYCLIQUES, N'-PYRAZOLYL-URÉE, THIOURÉE, GUANIDINE ET CYANOGUANIDINE UTILES COMME INHIBITEURS DE TRKA KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078325A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  化合物的公式(I)或其立体异构体、互变异构体、或其药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。